Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kenneth W. Mahaffey"'
Autor:
W. Schuyler Jones, Iris Baumgartner, Brian G. Katona, Peter Held, F. Gerry R. Fowkes, Kenneth W. Mahaffey, Manesh R. Patel, William R. Hiatt, Christoph B. Olivier, Juuso I. Blomster, Frank W. Rockhold, Hillary Mulder, Lars Norgren, Jeffrey S. Berger
Publikováno v:
JAMA Cardiology. 4(1):7-15
IMPORTANCE: Patients with peripheral artery disease (PAD) are at high risk for myocardial infarction (MI). OBJECTIVE: To characterize the incidence and types of MI in a PAD population, identify factors associated with MI, and determine the associatio
Autor:
Kenneth W. Mahaffey, Larry A. Allen, James A. Reiffel, DaJuanicia N. Holmes, Utibe R. Essien, Jonathan P. Piccini, James V. Freeman, Daniel E. Singer, Benjamin A. Steinberg, Rosalia Blanco, Gregg C. Fonarow, Paul Chan, Larry R. Jackson, Eric D. Peterson, Karen S. Pieper
Publikováno v:
JAMA cardiology. 3(12)
IMPORTANCE: Black and Hispanic patients are less likely than white patients to use oral anticoagulants for atrial fibrillation. Little is known about racial/ethnic differences in use of direct-acting oral anticoagulants (DOACs) for atrial fibrillatio
Autor:
DaJuanicia N. Holmes, Sean D. Pokorney, Jonathan P. Piccini, Eric D. Peterson, Michael D. Ezekowitz, Laine Thomas, Kenneth W. Mahaffey, Peter R. Kowey, Gerald V. Naccarelli, James A. Reiffel, Bernard J. Gersh, Gregg C. Fonarow, Elaine M. Hylek, Daniel E. Singer, James V. Freeman
Publikováno v:
JAMA Cardiology. 4:756
Importance Bleeding and thrombotic events (eg, stroke and systemic embolism) are common in patients with atrial fibrillation (AF) taking warfarin sodium despite a well-established therapeutic range. Objective To evaluate whether history of therapeuti
Autor:
Anders Himmelmann, Daniel Lindholm, Christopher P. Cannon, Robert F. Storey, Stefan James, Philippe Gabriel Steg, Katja Gabrysch, Claes Held, Kenneth W. Mahaffey, Lars Wallentin, Agneta Siegbahn
Publikováno v:
JAMA Cardiology. 3:1160
Importance Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. Objective To assess if different b
Autor:
Alberto Menozzi, Robert A. Harrington, Steven Elkin, Muthiah Vaduganathan, Harvey D. White, Jayne Prats, Deepak L. Bhatt, Ph. Gabriel Steg, Gregg W. Stone, Kenneth W. Mahaffey, Efthymios N. Deliargyris, Matthew J. Price, C. Michael Gibson, Christian W. Hamm
Publikováno v:
JAMA Cardiology. 2:127
Importance In the context of contemporary pharmacotherapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been well established. Objective To compare the ischemic and bleeding risks associated with glycoprotein
Autor:
John H. Alexander, Harvey D. White, Jonathan P. Piccini, Yuliya Lokhnygina, Matthew T. Roe, Daniel M. Wojdyla, Claes Held, David J. Moliterno, Lars Wallentin, Kenneth W. Mahaffey, Paul L. Hess, Pierluigi Tricoci, Sana M. Al-Khatib, Paul W. Armstrong, Philip E. Aylward, Frans Van de Werf, E. Magnus Ohman, Robert A. Harrington
Publikováno v:
JAMA Cardiology. 1:73
In the current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevation acute coronary syndrome (NSTE ACS) has not been characterized completely.To determine the cumulative incidence of SCD during long-term follow-up af